insulin cost cap study Medicare reveals lower drug costs and better diabetes control, raising questions about expanding similar policies in California.
A new national study published in JAMA Internal Medicine is offering one of the clearest looks yet at how lowering drug costs can reshape health outcomes. For California, where millions struggle with chronic disease and rising medical bills, the findings arrive at a critical moment.
The research tracked 4.8 million Medicare patients with Type 2 diabetes between 2019 and 2023 and evaluated the federal $35 monthly insulin cap. The results point to a simple but powerful conclusion. When insulin becomes affordable, people use it more consistently and their health improves.
That insight carries particular weight for Latino communities. According to the Centers for Disease Control and Prevention, Latinos are significantly more likely to be diagnosed with diabetes than non Latino white adults, while also facing higher uninsured rates and cost barriers to care.
The study found that out of pocket insulin spending dropped sharply. Patients saved about $106 per quarter on average, and the share paying more than $35 for a monthly supply fell from over 60 percent in 2019 to almost zero by late 2023.
Researchers also observed improved medication adherence. Patients used more consistent insulin doses, a signal that fewer were rationing due to cost. Average A1c levels, a key measure of blood sugar control, declined modestly.
“This is what access looks like,” said Dr. Kasia Lipska, who studies diabetes treatment and affordability. “When patients can afford their medications, they are more likely to take them as prescribed, and that translates into better outcomes.”
There was a slight increase in hypoglycemia events, likely tied to higher insulin use, underscoring the need for ongoing clinical monitoring.
For years, high insulin prices have driven patients to skip doses or delay treatment, leading to emergency complications such as diabetic ketoacidosis. Those episodes are not only life threatening but expensive.
A 2025 analysis from RAND Corporation found that better medication adherence can initially increase healthcare utilization as patients re engage with the system. But over time, experts say the shift toward preventive care reduces costly hospitalizations.
Estimates cited in diabetes research suggest that properly managing a single patient can reduce overall healthcare costs by thousands of dollars annually.
One surprising finding from the study is that lower costs did not lead to more patients starting insulin therapy. Researchers say affordability alone does not solve barriers such as delayed diagnosis, limited access to specialists, or fear of starting insulin.
“This tells us cost is only one piece of the puzzle,” said Dr. Elbert Huang, an expert in chronic disease management. “We need earlier screening, better patient education, and stronger primary care systems.”
California’s experiment could go further
California is already testing a more aggressive approach. Through its CalRx initiative, the state is working with manufacturers to produce low cost insulin, aiming to sell it at about $30 per vial regardless of insurance status.
Backers say this model could extend the benefits seen in Medicare to younger, working age populations, including uninsured Latinos who are often excluded from federal protections.
The bigger question is whether cost caps alone are enough. The evidence suggests they are a powerful first step, but not a complete solution.
For communities already carrying a disproportionate burden of diabetes, the stakes are high. Lower prices can open the door to care, but lasting change will depend on whether the healthcare system meets patients on the other side of that door.
